(untitled) - Werth, V; Hajazi, E; Pena, S
et al. A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Refractory Skin-Predominant Dermatomyositis (abstract). Arthritis Rheumatol 2017; 69